Valuation: 4D Molecular Therapeutics, Inc.

Market Cap 671M 596M 553M 503M 949M 63.65B 964M 6.64B 2.6B 33.22B 2.52B 2.46B 106B P/E 2026 *
-2.93x
P/E 2027 * -3.04x
Enterprise Value 476M 423M 392M 356M 673M 45.13B 683M 4.71B 1.85B 23.55B 1.78B 1.75B 75.08B EV / Sales 2026 *
35.9x
EV / Sales 2027 * 16.3x
Free-Float
97.28%
Yield 2026 *
-
Yield 2027 * -
1 day-5.67%
1 week-8.93%
Current month-15.16%
1 month-20.24%
3 months+10.46%
6 months+15.73%
Current year+61.87%
1 week 11.99
Extreme 11.99
13.01
1 month 11.99
Extreme 11.99
16.23
Current year 6.96
Extreme 6.96
16.93
1 year 6.96
Extreme 6.96
16.93
3 years 2.24
Extreme 2.235
36.25
5 years 2.24
Extreme 2.235
36.25
10 years 2.24
Extreme 2.235
55.11
Manager TitleAgeSince
Chief Operating Officer 51 2018-03-31
Chief Executive Officer 64 2013-09-11
Director of Finance/CFO 51 2025-11-16
Director TitleAgeSince
Chairman 64 2013-09-11
Director/Board Member 62 2015-11-30
Director/Board Member 47 2019-02-28
Date Insider Type Main position Quantity % Market Cap. Importance
10/5/26 Sell

Founder

-58,333 0.1056%
9/16/26 Exercice

Compliance Officer

4,905 0.0089%
9/14/26 Sell

Founder

-58,333 0.1056%
Change 5-day change 1-year change 3-year change Capi.($)
-5.67%-8.93%+23.37%+16.62% 671M
-6.60%-8.56%+49.38%+64.90% 65B
+0.03%+5.56%+9.10%+75.22% 51.2B
-4.09%-0.11%+2.22%+55.67% 51.19B
-1.53%+2.70%+30.48%+41.25% 43.93B
-1.34%+4.12%+16.64%+120.28% 41.96B
-5.97%-6.22%+228.95%+483.48% 38.14B
+6.53%+8.02%+16.40%+56.32% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
-1.07%+2.33%+19.43%+20.40% 22.5B
Average -2.06%-1.21%+43.31%+93.59% 37.3B
Weighted average by Cap. -2.20%-0.51%+44.21%+103.50%

Financials

2026 *2027 *
Net sales 13.26M 11.78M 10.92M 9.94M 18.75M 1.26B 19.05M 131M 51.47M 657M 49.75M 48.69M 2.09B 20.63M 18.34M 17M 15.47M 29.19M 1.96B 29.65M 204M 80.12M 1.02B 77.44M 75.79M 3.26B
Net income -289M -257M -238M -216M -408M -27.39B -415M -2.86B -1.12B -14.29B -1.08B -1.06B -45.56B -316M -281M -261M -237M -447M -30.01B -454M -3.13B -1.23B -15.66B -1.19B -1.16B -49.93B
Net Debt -195M -173M -161M -146M -276M -18.52B -280M -1.93B -758M -9.67B -732M -717M -30.81B -334M -297M -275M -250M -473M -31.71B -480M -3.31B -1.3B -16.55B -1.25B -1.23B -52.75B
Projected Income Statement - Annual - 4D Molecular Therapeutics, Inc.
Logo 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.
Employees
196
Date Price Change Volume
26-10-16 US$12.14 -5.67% 794,535
26-10-15 US$12.87 +5.49% 787,613
26-10-14 US$12.20 -1.29% 632,964
26-10-13 US$12.36 -4.92% 991,721
26-10-12 US$13.00 -2.48% 835,835
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - 4D Molecular Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
12.14USD
Average target price
28.09USD
Spread / Average Target
+131.39%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - 4D Molecular Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. FDMT Stock